Phenominer Database Results (12 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Site Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Record ID Study ID
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 8 62.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67855 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 10 40.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67856 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 8 37.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68204 829
DA.ACI-(D10Rat15-D10Rat29) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 12 3.5 d 1.7 5.89 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68194 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 10 30.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68213 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 13 30.8 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days relap, % 68228 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 12 8.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68195 829
DA.ACI-(D10Rat15-D10Rat29) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 4 8.7 d 2.8 5.6 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68212 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 12 33.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67848 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 13 76.9 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67859 829
DA.ACI-(D10Rat15-D10Rat29) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 5 13.4 d 2.0 4.47 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68203 829
DA.ACI-(D10Rat15-D10Rat29) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 10 8.6 d 1.5 4.74 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68227 829